| |
Jay - Another pathetic post!!
<<<Tell me what you think about this story....>>>
OK - here's what I think...
Edgar shows the following for Zonagen (full year ending 12/31/97)& Pharmaprint (6 months ending 9/30/97) (sorry about the format)
Zonagen
Cash in bank - $ 73,762K
Net Income - (13,173)
Net Cash Flow - (8,255)
Pharmaprint
Cash in bank - $ 3,281K
Net Income - (8,204)
Net Cash Flow - (4,829)
I think this story has ABSOLUTELY NOTHING in common with Zonagen. With another with another $47 Million in milestone payments already committed by SGP, Zona has several YEARS of cash available.
By 12/31 Pharmaprint was probably running on fumes - so they raised money. What the hell does this have in common with Zonagen today?
Just explain why a cash rich company like Zonagen would be planning another offering? No, just another cheap shot.
<<<I will inundate you with countless other examples of this phenomenon if you like. We'll start with Connectix and Dillon Read.>>>
Connectix is a privately held corporation with no financial info publicly available.
Please don't innundate me with similar examples. Here's what you need to provide me with -
a development stage biotech firm with its first compound through clinical trials, with a major pharma partner that is filing the NDA, with milestone payments already received and others coming, with YEARS of cash in the bank, with a new buy recommendation from a major brokerage/investent banking firm - THEN that brokerage firm participating in a financing round shortly after issuing the rec.
Short of that - get a life. |
|
